Overall, we found a molecular mechanism of CCL2 overexpression in the bladder cancer and showed that treatment targeting FAM171B would be an effective approach for bladder cancer patients with high TAM infiltration. The gene discussed is CCL2; the disease is urinary bladder carcinoma.